145
Views
9
CrossRef citations to date
0
Altmetric
Research Article

In silico screening and identification of potential GSK3β inhibitors

, &
Pages 279-289 | Received 21 Oct 2017, Accepted 05 Dec 2017, Published online: 27 Jun 2018
 

Abstract

Glycogen synthase kinase-3β (GSK3β) has been reported for its impact on multitude biological processes from cell proliferation to apoptosis. The increase in the ratio of active/inactive GSK3β is the major factor associated in the etiology of several psychiatric diseases, diabetes, muscle hypertrophy, neurodegenerative diseases, and some cancers. These findings made GSK3β a promising therapeutic target, and the interest in the discovery, synthesis of novel drugs to effectively attenuate its function with probably no side effects has been increasing in the chronology of GSK3β drug discovery. In the present study, we applied a combination of computational tools on a chemical library for the virtual discovery of their potency to inhibit GSK3β. The chemical library was screened against a set of filters at different levels. Finally, five compounds in the chemical library were found to potentially inhibit GSK3β with no toxic effects. Furthermore, binding mode analysis revealed that all the compounds bound to the ATP site and most of the hydrogen bonding interactions are conserved as in GSK3β structures deposited in PDB.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

DT is thankful to University Grants Commission, New Delhi for financial support in the form of UGC – BSR (RFSMS) Senior Research Fellowship. YS is thankful to Human Resource Development for Health Research, New Delhi (F.No.V0.25011/542-HRD/2016-HR).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.